Hofseth BioCare Balans Gezondheid

Financiële gezondheid criteriumcontroles 2/6

Hofseth BioCare heeft een totaal eigen vermogen van NOK137.5M en een totale schuld van NOK177.5M, wat de schuld-eigenvermogensverhouding op 129.1% brengt. De totale activa en totale passiva bedragen respectievelijk NOK385.5M en NOK248.0M.

Belangrijke informatie

129.1%

Verhouding schuld/eigen vermogen

NOK 177.52m

Schuld

Rente dekkingsratio	n/a
Contant	NOK 25.30m
Aandelen	NOK 137.55m
Totaal verplichtingen	NOK 247.98m
Totaal activa	NOK 385.53m

Recente financiële gezondheidsupdates

Recent updates

Here's Why Hofseth BioCare (OB:HBC) Can Afford Some Debt

Apr 01

We Think Hofseth BioCare (OB:HBC) Has A Fair Chunk Of Debt

Dec 22

Health Check: How Prudently Does Hofseth BioCare (OB:HBC) Use Debt?

Apr 28

Hofseth BioCare (OB:HBC) Is Carrying A Fair Bit Of Debt

Oct 16

Is Hofseth BioCare (OB:HBC) Using Debt Sensibly?

Feb 24

How Much Of Hofseth BioCare ASA (OB:HBC) Do Insiders Own?

Jan 28

Are Insiders Buying Hofseth BioCare ASA (OB:HBC) Stock?

Dec 25

Hofseth BioCare (OB:HBC) Shareholders Have Enjoyed A Whopping 339% Share Price Gain

Nov 20

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( NOK135.8M ) van HBC } dekken niet de korte termijn passiva ( NOK155.5M ).

Langlopende schulden: De kortetermijnactiva HBC ( NOK135.8M ) overtreffen de langetermijnschulden ( NOK92.5M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: De netto schuld/eigen vermogen ratio ( 110.7% ) HBC wordt als hoog beschouwd.

Schuld verminderen: De schuld/eigen vermogen-ratio van HBC is de afgelopen 5 jaar gedaald van 250.3% naar 129.1%.

Balans

Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: HBC heeft minder dan een jaar aan cash runway op basis van de huidige vrije kasstroom.

Voorspelling contante baan: HBC heeft minder dan een jaar aan kasmiddelen beschikbaar als de vrije kasstroom blijft groeien met een historisch percentage van 5.4 % per jaar.

Hofseth BioCare Balans Gezondheid

Financiële gezondheid criteriumcontroles 2/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Here's Why Hofseth BioCare (OB:HBC) Can Afford Some Debt

We Think Hofseth BioCare (OB:HBC) Has A Fair Chunk Of Debt

Health Check: How Prudently Does Hofseth BioCare (OB:HBC) Use Debt?

Hofseth BioCare (OB:HBC) Is Carrying A Fair Bit Of Debt

Is Hofseth BioCare (OB:HBC) Using Debt Sensibly?

Recent updates

Hofseth Biocare Asa Announces Resignation of Christel Elise Kanli as CFO

Hofseth Biocare Asa Announces Resignation of Christel Elise Kanli as CFO

New minor risk - Shareholder dilution

Second quarter 2024 earnings released: kr0.04 loss per share (vs kr0.015 profit in 2Q 2023)

Less than half of directors are independent

First quarter 2024 earnings released: kr0.07 loss per share (vs kr0.096 loss in 1Q 2023)

Full year 2023 earnings released: kr0.27 loss per share (vs kr0.37 loss in FY 2022)

New minor risk - Share price stability

Hofseth BioCare ASA Announces Board Changes

New major risk - Financial position

Full year 2023 earnings released: kr0.27 loss per share (vs kr0.37 loss in FY 2022)

Hofseth BioCare ASA to Report Q4, 2024 Results on Feb 14, 2025

Third quarter 2023 earnings released: kr0.06 loss per share (vs kr0.09 loss in 3Q 2022)

New minor risk - Market cap size

Second quarter 2023 earnings released: EPS: kr0.015 (vs kr0.079 loss in 2Q 2022)

CFO & COO recently bought kr200k worth of stock

New minor risk - Market cap size

Hofseth Biocare ASA Announces the Online Publication of Its Abstract

First quarter 2023 earnings released: kr0.10 loss per share (vs kr0.10 loss in 1Q 2022)

Here's Why Hofseth BioCare (OB:HBC) Can Afford Some Debt

Chief Scientific Officer recently bought kr538k worth of stock

Independent Director recently bought kr272k worth of stock

Full year 2022 earnings released: kr0.37 loss per share (vs kr0.35 loss in FY 2021)

We Think Hofseth BioCare (OB:HBC) Has A Fair Chunk Of Debt

Hofseth BioCare ASA to Report Fiscal Year 2022 Results on Mar 31, 2023

Third quarter 2022 earnings released: kr0.09 loss per share (vs kr0.11 loss in 3Q 2021)

Third quarter 2022 earnings released: kr0.09 loss per share (vs kr0.11 loss in 3Q 2021)

Hofseth BioCare ASA's Progo Bioactive Peptides Now Is A "New Dietary Ingredient" for the US FDA

Second quarter 2022 earnings released: kr0.08 loss per share (vs kr0.069 loss in 2Q 2021)

Hofseth BioCare ASA Announces Executive Changes

Chief Executive Officer recently bought kr170k worth of stock

First quarter 2022 earnings released: kr0.10 loss per share (vs kr0.075 loss in 1Q 2021)

Health Check: How Prudently Does Hofseth BioCare (OB:HBC) Use Debt?

Full year 2021 earnings released: kr0.35 loss per share (vs kr0.31 loss in FY 2020)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Chief Executive Officer recently bought kr367k worth of stock

Hofseth Biocare ASA Successfully Receive New Dietary Ingredient (NDI) Status from the US FDA

Third quarter 2021 earnings released: kr0.11 loss per share (vs kr0.10 loss in 3Q 2020)

Hofseth BioCare (OB:HBC) Is Carrying A Fair Bit Of Debt

Chief Commercial Officer recently bought kr200k worth of stock

Chief Executive Officer recently bought kr361k worth of stock

Second quarter 2021 earnings released: kr0.07 loss per share (vs kr0.062 loss in 2Q 2020)

Hofseth BioCare ASA Provides Earnings Guidance for the Second Half of 2021 and Next Year 2022

Independent Director recently bought kr385k worth of stock

First quarter 2021 earnings released: kr0.08 loss per share (vs kr0.055 loss in 1Q 2020)

Full year 2020 earnings released: kr0.31 loss per share (vs kr0.29 loss in FY 2019)

Is Hofseth BioCare (OB:HBC) Using Debt Sensibly?

Full year 2020 earnings released: kr0.31 loss per share (vs kr0.29 loss in FY 2019)

How Much Of Hofseth BioCare ASA (OB:HBC) Do Insiders Own?

Chief Executive Officer recently bought kr505k worth of stock

Chief Executive Officer recently bought kr505k worth of stock

Chief Executive Officer recently bought kr505k worth of stock

New 90-day high: kr9.80

Are Insiders Buying Hofseth BioCare ASA (OB:HBC) Stock?

Hofseth BioCare ASA has completed a Follow-on Equity Offering in the amount of NOK 39.999995 million.

Hofseth Biocare ASA and Tenet Partners Initiate A Long-Term Collaboration to Build A Global Brand and Launch HBC Own Branded Consumer Health Products

Hofseth BioCare ASA and DKSH Announces A Pan-Asian Exclusive Collaboration for Distribution of HBC Branded Products Including Across China, India, Japan & Korea

Hofseth Biocare Asa Signs Exclusive Distribution Agreement with Leading Speciality Chemicals and Ingredients Distributor IMCD

Hofseth Biocare ASA Hires Andy Gill as VP from January 2021

Hofseth BioCare ASA, Annual General Meeting, Apr 23, 2021

Hofseth BioCare (OB:HBC) Shareholders Have Enjoyed A Whopping 339% Share Price Gain

Hofseth Biocare ASA Approves Appointment of Christoph Baldegger as New Member of the Audit Committee

Third quarter earnings released

New 90-day low: kr7.98

HBC Receives Approval from Health Canada for Qualified Health Claims Focused on Maintaining Healthy Levels of Ferritin and Hemoglobin and the Blood Components Required for Oxygen Transport

Hofseth BioCare ASA has completed a Follow-on Equity Offering in the amount of NOK 200 million.

Hofseth Biocare ASA's Progo’s Bioactive Peptides to Support Healthy Iron Levels to Be Launched in the US

Hofseth BioCare ASA Announces the First Part of its Accelerated Phase 2 Trial of Cardio™ Soft Gels for the Treatment of Patients with COVID-19

New 90-day low - kr8.16

First half earnings released